Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses.

[1]  J. Sidney,et al.  Derivation of HLA-A11/Kb transgenic mice: functional CTL repertoire and recognition of human A11-restricted CTL epitopes. , 1997, Journal of immunology.

[2]  H. Grey,et al.  The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. , 1997, Journal of immunology.

[3]  R W Chesnut,et al.  Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. , 1997, Immunity.

[4]  L. BenMohamed,et al.  Lipopeptide immunization without adjuvant induces potent and long‐lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees , 1997, European journal of immunology.

[5]  Lunli Yuan,et al.  Comparison of cytotoxic T lymphocyte responses induced by peptide or DNA immunization: Implications on immunogenicity and immunodominance , 1997, European journal of immunology.

[6]  P. Parham,et al.  Polymorphism in the alpha 1 helix of the HLA-B heavy chain can have an overriding influence on peptide-binding specificity. , 1997, Journal of immunology.

[7]  J. Sidney,et al.  Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. , 1997, Journal of immunology.

[8]  R. Phillips,et al.  Escape of human immunodeficiency virus from immune control. , 1997, Annual review of immunology.

[9]  J. Sidney,et al.  Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection. , 1996, Journal of immunology.

[10]  A. Vitiello,et al.  Immunodominance analysis of CTL responses to influenza PR8 virus reveals two new dominant and subdominant Kb-restricted epitopes. , 1996, Journal of immunology.

[11]  M F del Guercio,et al.  Specificity and degeneracy in peptide binding to HLA-B7-like class I molecules. , 1996, Journal of immunology.

[12]  J. Manuguerra,et al.  Protection against lethal viral infection by vaccination with nonimmunodominant peptides. , 1996, Journal of immunology.

[13]  A Sette,et al.  Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. , 1996, Journal of immunology.

[14]  X. Mo,et al.  Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. , 1996, Journal of immunology.

[15]  C. Bordignon,et al.  Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A*0201+ cytotoxic T cell line. , 1996, Journal of immunology.

[16]  A Sette,et al.  Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. , 1996, Immunology today.

[17]  A Sette,et al.  Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes , 1996, The Journal of experimental medicine.

[18]  J. Gralow,et al.  Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. , 1996, Journal of immunology.

[19]  C. Sergheraert,et al.  Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTL. , 1996, Vaccine.

[20]  J. Guillet,et al.  Influence of strong CD4 epitope on long-term virus-specific cytotoxic T cell responses induced in vivo with peptides. , 1996, International immunology.

[21]  J. Berzofsky,et al.  Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. , 1996, Journal of immunology.

[22]  F. Chisari,et al.  Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. , 1996, The Journal of clinical investigation.

[23]  S. Hoffman,et al.  Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity , 1996, The Journal of experimental medicine.

[24]  M F del Guercio,et al.  Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules. , 1996, Human immunology.

[25]  A. Vitiello,et al.  Differences and similarities in the A2.1‐restricted cytotoxic T cell repertoire in humans and human leukocyte antigen‐transgenic mice , 1996, European journal of immunology.

[26]  J. Berzofsky,et al.  Use of intrinsic and extrinsic helper epitopes for in vivo induction of anti-hepatitis C virus cytotoxic T lymphocytes (CTL) with CTL epitope peptide vaccines. , 1996, The Journal of infectious diseases.

[27]  M. Mottolese,et al.  Expression of the mage gene family in primary and metastatic human breast cancer: Implications for tumor antigen‐specific immunotherapy , 1995, International journal of cancer.

[28]  D J Moss,et al.  Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[29]  H. Grey,et al.  Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. , 1995, Journal of immunology.

[30]  F. Chisari,et al.  Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. , 1995, The Journal of clinical investigation.

[31]  P. Parham,et al.  Overlap in the repertoires of peptides bound in vivo by a group of related class I HLA-B allotypes , 1995, Current Biology.

[32]  F. Chisari,et al.  Hepatitis B virus immunopathogenesis. , 1995, Annual review of immunology.

[33]  M F del Guercio,et al.  Several HLA alleles share overlapping peptide specificities. , 1995, Journal of immunology.

[34]  D. O'hagan,et al.  Protection of mice from Bordetella pertussis respiratory infection using microencapsulated pertussis fimbriae. , 1995, Vaccine.

[35]  A. Vitiello,et al.  Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. , 1995, The Journal of clinical investigation.

[36]  B. Rouse,et al.  Priming for virus-specific CD8+ but not CD4+ cytotoxic T lymphocytes with synthetic lipopeptide is influenced by acylation units and liposome encapsulation. , 1995, Vaccine.

[37]  C Oseroff,et al.  Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. , 1994, Immunity.

[38]  K. Wiesmüller,et al.  Efficacy of synthetic vaccines in the induction of cytotoxic T lymphocytes. Comparison of the costimulating support provided by helper T cells and lipoamino acid. , 1994, Journal of immunological methods.

[39]  J. Berzofsky,et al.  An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans , 1994, Journal of virology.

[40]  V. Engelhard,et al.  Structure of peptides associated with class I and class II MHC molecules. , 1994, Annual review of immunology.

[41]  R. Gupta,et al.  Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. , 1994, Vaccine.

[42]  P. Bruggen,et al.  Tumor antigens recognized by T lymphocytes. , 1994, Annual review of immunology.

[43]  B. Nardelli,et al.  Oral administration of an antigenic synthetic lipopeptide (MAP-P3C) evokes salivary antibodies and systemic humoral and cellular responses. , 1994, Vaccine.

[44]  A. Capron,et al.  Effect of a lipopeptidic formulation on macrophage activation and peptide presentation to T cells. , 1994, Vaccine.

[45]  Seamus J. Martin,et al.  Immunization of human HIV‐seronegative volunteers with recombinant p17/p24: Ty virus‐like particles elicits HIV‐1 p24‐specific cellular and humoral immune responses , 1993, AIDS.

[46]  A. Kingsman,et al.  Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion , 1993, Journal of virology.

[47]  A. Vitiello,et al.  HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. , 1993, Journal of immunology.

[48]  F. Chisari,et al.  HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis , 1993, The Journal of experimental medicine.

[49]  J. Whitton,et al.  A "string-of-beads" vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge , 1993, Journal of virology.

[50]  H. Rammensee,et al.  Peptides naturally presented by MHC class I molecules. , 1993, Annual review of immunology.

[51]  R. Germain,et al.  The biochemistry and cell biology of antigen processing and presentation. , 1993, Annual review of immunology.

[52]  J. Schlom,et al.  Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. , 1992, Journal of the National Cancer Institute.

[53]  B. Rouse,et al.  In vivo cytotoxic T lymphocyte induction with soluble proteins administered in liposomes. , 1992, Journal of immunology.

[54]  F. Chisari,et al.  HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[55]  A. Vitiello,et al.  Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex , 1991, The Journal of experimental medicine.

[56]  J. Mcghee,et al.  Biodegradable microspheres as a vaccine delivery system. , 1991, Molecular immunology.

[57]  F. Grunert,et al.  Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives , 1991, Journal of clinical laboratory analysis.

[58]  J. Berzofsky,et al.  Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs , 1990, Nature.

[59]  Antonio Lanzavecchia,et al.  Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells , 1989, European journal of immunology.

[60]  H. Rammensee,et al.  In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine , 1989, Nature.

[61]  L. Sherman,et al.  Species-restricted interactions between CD8 and the alpha 3 domain of class I influence the magnitude of the xenogeneic response , 1989, The Journal of experimental medicine.

[62]  R. Demars,et al.  Production of human cells expressing individual transferred HLA-A,-B,-C genes using an HLA-A,-B,-C null human cell line. , 1989, Journal of immunology.

[63]  R. Sheppard,et al.  Solid phase peptide synthesis : a practical approach , 1989 .

[64]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.